Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg; Combination Product · Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 3,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more

Conditions: Asthma
Interventions: fluticasone propionate and salmeterol, budesonide and formoterol; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI; Combination Product · Drug · Other
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more

Conditions: Asthma
Interventions: Albuterol Sulfate, Albuterol-Budesonide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more

Conditions: COPD, COPD Exacerbation
Interventions: Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Asthma, Lung Diseases
Interventions: Inhaled Corticosteroid (Budesonide), Leukotriene Receptor Antagonist (Montelukast Sodium), Inhaled Albuterol; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 12 Months to 59 Months
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 6
States / cities: Tucson, Arizona • La Jolla, California • Denver, Colorado + 3 more

Conditions: Relative Bioavailability
Interventions: BDA MDI 160/180 mcg, Pulmicort Flexhaler 180 mcg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Albuterol and budesonide inhalation aerosol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Budesonide, budesonide/formoterol, Ipratropium/albuterol; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 45 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more

Conditions: Asthma
Interventions: BDA MDI, AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 113
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 91 more

Conditions: Asthma
Interventions: BDA MDI, AS MDI; Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 12 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more

Conditions: Asthma
Interventions: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more

Conditions: Asthma
Interventions: Budesonide, albuterol, Ipratropium bromide, Prednisone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: East Meadow, New York • Queens, New York • The Bronx, New York

Conditions: Asthma in Children
Interventions: Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI; Drug
Lead sponsor: Allergy and Asthma Center of El Paso; Other
Eligibility: 12 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Asthma
Interventions: Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Asthma
Interventions: None (observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Interventions: Budesonide-albuterol, Benralizumab; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Heathy Participants
Interventions: Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

Ventilation and Perfusion in Asthmatics

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Fasenra: An Asthma Study

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.